When cancer hits, the cost of treatment shouldn’t bite
Cancer changes a family’s life in an instant. Patients and their loved ones must confront difficult decisions about treatment, finances and the future. For many households, medicine costs become an added burden at a time when every resource should be devoted to recovery. A compassionate health system must respond to the financial distress the disease causes.
Keeping this in mind, the Union government has rationalised trade margins for 137 identified non-scheduled anti-cancer drugs: The National Pharmaceutical Pricing Authority (NPPA) capped the margins at 30% of the maximum retail price (MRP). The revised prices came into effect on November 9, 2026. The price a patient pays must reflect fair and reasonable distribution margins, not excessive mark-ups.
The results are already visible at the pharmacy counter. Over 80 pharmaceutical companies have notified revised MRPs for 1,366 products covering 121 of the 137 drugs. Prices have fallen for more than four out of every five of these products. For nearly half of them, the reduction is more than 50%; some even cost 96% less now. For a family paying for repeated cycles of chemotherapy, this makes a real difference to monthly treatment bills. Based on last year’s consumption, patients and their families are expected to save about........
